TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) issued its earnings results on Wednesday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02), Zacks reports. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

TScan Therapeutics Stock Down 3.0 %

Shares of TScan Therapeutics stock traded down $0.06 during trading hours on Wednesday, reaching $1.96. 53,025 shares of the company were exchanged, compared to its average volume of 308,753. TScan Therapeutics has a 1 year low of $1.82 and a 1 year high of $9.69. The stock’s fifty day moving average is $2.47 and its 200 day moving average is $4.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm has a market cap of $104.61 million, a PE ratio of -1.89 and a beta of 0.87.

Analysts Set New Price Targets

A number of research firms recently commented on TCRX. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.